All News

At a state-of-the-art facility in Thousand Oaks, California, drugmaker Amgen Inc. is perfecting the art of copying others, and it must work fast because copycats are already coming for Amgen's drugs.

Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society's 97th annual meeting.

Congress came close to adopting a value-based payment formula for physicians last year, but the problem of funding the SGR, which has grown to $175 billion, prevents a solution.

Letting patients see their medical records while they're in the hospital might ease worry and confusion without extra work for doctors and nurses, a small study suggests.

Commissioned by The Leukemia and Lymphoma Society, the results of the study help make the case for placing limits on out-of-pocket costs for patients that would relieve their financial burden without a significant impact to insurers.

Just 2 therapy classes are responsible for more than half of the increase in overall prescription drug spending in the United States, reported Express Scripts.

Oregon Gov Kate Brown signed a bill shutting down the troubled, and expensive, state health insurance exchange, Cover Oregon.

A study, published in the journal Cancer, found that women with a family history of both breast and prostate cancer among first-degree relatives have an almost 2-fold increase in risk of developing breast cancer themselves.

One of the criticisms, which came from ASCO, points to the absence of consideration for patient heterogeneity that can result in physicians being penalized for providing patient-centered treatment.

Evidence-Based Oncology: Future of Incentive-Driven Pathway Adherence, developed in collaboration with Healthcare Research & Analytics (HRA), outlines what the real impact of clinical pathways are on the oncology practice and what the key drivers of clinical pathways use are for both payers and providers.

AJMC is proud to bring you an educational webinar that will provide reasons & examples on why you should engage with customers before they\'re your customers.

AJMC is proud to bring you an educational webinar that will tell how innovative data curation methods can provide well-informed, actionable business strategies for the evolving healthcare landscape.

AJMC is proud to bring you the first in our series of educational webinars to help our readers and customers better understand some of the trends, challenges and opportunities in the managed care segment

New Hampshire's waiver features premium assistance to shop on the HealthCare.gov exchange and includes a work-referral requirement. CMS resisted linking a waiver to work-related requirements more than a year ago when granting Pennsylvania's waiver.

While sunitinib failed as adjuvant treatment in advanced kidney cancer, this phase 2 study presented at the ongoing annual meeting of The Endocrine Society found that in patients with advanced thyroid cancer, sunitinib treatment resulted in median progression free survival of about 8 months. The authors think their results create sufficient evidence to initiate a phase 3 trial of the drug in thyroid cancer patients.

Kansas health regulators are working to repeal a 2002 law prohibiting the state from regulating mental health drugs used for treating Medicaid patients. Doing so could potentially save the state about $7 million.

New oncology payment models, 340B pricing and disproportionate share hospitals, and the significant difference in reimbursement rates for cancer care services are just some of the challenges faced by community oncology clinics. How do patients make informed decisions on where to go for care?

In an era when most industries easily share big, complicated digital files, healthcare still leans hard on paper printouts and fax machines.

A group of 700 independent Portland doctors, both primary care and specialty, have come together to for a new accountable care organization.

While the wearable market itself has tremendous potential, its effect on the health insurance industry could be just as significant.

Despite the measles outbreak resulting from the anti-vaccination movement in the United States, the percent of Americans who said it's "extremely important" to get children vaccinated continued to fall, according to a new Gallup poll.

A one-minute look at managed care news during the week of March 2, 2015, including oral arguments for King v. Burwell and the approval of the first biosimilar in the United States.

Antelope Valley Hospital in Lancaster, California, shut down its emergency department after the electronic health record and data system failed and the hospital had no backup plan in place.

HHS has released a plan to expand how its agencies make research results freely available to scientists and the public.

The second open enrollment period for the Affordable Care Act went much smoother for consumers signing up for health plans through HealthCare.gov; however, CMS still has much work to do, according to a new report from the Government Accountability Office.

The study, conducted at the Dana-Farber Cancer Institute and published in the Journal of the National Cancer Institute found that the benefits of these personalized cancer products are reported much more frequently than are the limitations.

In a 3-month review of cyber risk management practices in healthcare, the Health Information Trust Alliance (HITRUST) has found that the industry's approach is reactive, inefficient, and labor intensive.

Gilead will be providing Harvoni free of cost to conduct a 600-person trial co-sponsored by the National Institute of Allergy and Infectious Diseases to evaluate if primary care physicians and other healthcare providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians.

The study, published in the Journal of Clinical Oncology found that the 5-year survival with ipilimumab (18.2%) was double that with placebo (8.8%) and roughly double the historical survival rate of patients with stage IV melanoma (approximately 10%).

Today the FDA approved the first biosimilar product in the United States. Zarxio (filgrastim-sndz), from Sandoz, Inc, is biosimilar to Amgen Inc's Neupogen (filgrastim), which was first licensed in 1991.